Rigel Pharmaceuticals, Inc. (RIGL) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Rigel Pharmaceuticals, Inc. (RIGL)

RIGL 37.87

+33.8%

Nov 5 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: kenhott who wrote (285)	12/5/2005 12:27:17 PM
From: tuck	Read Replies (1) of 566

Did you in fact listen to the CC? I would recommend doing so. It seems to be more of a matter of potency & perhaps formulation (relating to various matters of PK/PD such as bioavailability, concentration, and so on) of the compound than validity of the target. This suggests follow-on compounds -- one of which is supposed to be 30x more potent -- have a decent chance. Further, the biology of RA is very different, and the compound aimed at it is systemic, while R112 for rhinitis was not. No, I think the target is fine, but the first shot on goal just went wide. Now, comments regarding how early the pipe is are nevertheless on target. We'll hear more about that on the 15th. I haven't attempted a valuation analysis, but if lots of people are thinking that Syk is a bad target, then Rigel may have been beaten up a bit too much. Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next